Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759842 | 1.00 | P2RY12 (0.39) | P2RY12ALOX15RAB9APDK2MGLL | |
| SCHEMBL22910813 | 0.91 | PDK2 (0.36) | P2RY12ALOX15RAB9APDK2MGLL | |
| SCHEMBL22911093 | 0.91 | MGLL (0.43) | P2RY12ALOX15MGLLNPC1 | |
| SCHEMBL16759905 | 0.91 | MGLL (0.43) | P2RY12ALOX15MGLLNPC1 | |
| SCHEMBL22910869 | 0.90 | ALOX15 (0.47) | P2RY12ALOX15MGLLHPGDROCK2 | |
| SCHEMBL16759873 | 0.90 | ALOX15 (0.47) | P2RY12ALOX15MGLLHPGDROCK2 | |
| SCHEMBL16759906 | 0.89 | TTK (0.36) | RAB9APDK2MGLLHPGDROCK2 | |
| SCHEMBL22911018 | 0.89 | TTK (0.36) | RAB9APDK2MGLLHPGDROCK2 | |
| SCHEMBL22911080 | 0.88 | FASN (0.37) | RAB9APDK2HPGDNPC1 | |
| SCHEMBL16759899 | 0.88 | FASN (0.37) | RAB9APDK2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | P2RY12 2685/4885ALOX15 1905/4885RAB9A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.